Tumor Immunology Round Table

How Alum adjuvant boost antigenic response

In this edition, I discuss the recent paper of Kool et al submitted to JEM, and where the authors evaluate the effect of aluminum adjuvant in antigen response. The authors found thad adjuvant mix results in the mobilization of phagocytes and monocytes to the peritoneal cavity upon i.p. injection of antigen, boosting antigen specific T cell response in the draining lymph nodes The most important observation found by authors was that inflammatory monocytes mobilized by adjuvant differentiate into matured dendritic cells and such cells are key elements in the antigen T cell response. A great reading... For reference please check the mouse lymph node localizations on this link. See you soon and have a nice listening

Efective anti-cancer immunotherapy with CD4 T cell clone

In this edition, I describe the manuscript published by the group of Cassian Yee to the New England Journal of Medicine entitled "Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1", that can be found in the volume 358 page 2698, of 2008 year series.

Anti-tumor role of {gamma}{delta} T cells in expontaneous prostate tumors

In this podcast I will describe a recent manuscript submitted by Liu et al to journal of Immunology 2008; 108:6044 , where {gamma}{delta} T cell knock-out mice were evaluated under situation of expontaneous prostate cancer (crossed with TRAMP mice) and in addition {gamma}{delta} T cells were also used in adoptive therapy settings against established tumors and metastatic disease. The authors show that under the experimental design setting that {gamma}{delta} T cells play a certain role in controlling tumor growth, by reducing the tumor burden and aggressiveness. See you next time

NKG2D mediated tumor immunity

Hi folks, Today I will do a short overview of a major manuscript published recently in journal immunity that presents data concerning the evaluation of NKG2D knock-out mice in the context of expontaneous tumor development. The format of the podcast has changed to fit in my time constrains. Let me know what do you think. See you soon, and thanks for listening

N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.

Hello In this edition of the podcast I will discuss a paper published by Demotte and collaborators published this year in the journal Immunity "Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes" vol 28, pag 414 of April 2008. In this paper the authors show that LacNAC can compete for galectin-3 binding freeing TCR from TIL to colocalize with CD8 and allow the recovery of efector functional on ex vivo freshly isolated TIL from ovarian cancer and gastric cancer. See you next time.